ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 0984

Predicting Risk of Infection in Hospitalized Patients with Rheumatic Diseases from the MIMIC-IV Clinical Database: A Machine Learning Approach
Abstract Number: 0225

Prediction of Response to Therapies and Flares Based on Ultrasound Findings at Baseline in Psoriatic Arthritis: An Analysis on a Joint Level
Abstract Number: 0613

Prediction of Spontaneous Abortion in Women with Systemic Lupus Erythematosus (SLE) Based on Machine Learning Model: Insights from the Egyptian College of Rheumatology (ECR)–SLE Cohort
Abstract Number: 2020

Prediction of the Response of Patients with Chronic Uncontrolled Gout to Pegloticase
Abstract Number: 0621

Predictive Parameters of Disease-related Damage Accrual in Patients with Systemic Lupus Erythematosus: A Machine Learning Analysis
Abstract Number: 2349

Predictive Potential of Serum Metabolites Associated with Treatment Response to Interleukin -17 Inhibitors in Patients with PsA
Abstract Number: 0641

Predictive Validity of Coronary Artery Calcium Scoring in Low Risk Systemic Lupus Erythematous Patients
Abstract Number: 1518

Predictive Value of Chronic Histologic Changes in Lupus Nephritis
Abstract Number: 1451

Predictors and Patterns of Fragility Fracture in an Observational Cohort of Patients with Psoriatic Arthritis
Abstract Number: 1670

Predictors of 6-Minute Walk Test Performance in Adults with Arthritis
Abstract Number: 0990

Predictors of Adverse Events and Complications in Cirrhotic Patients with Rheumatoid Arthritis: A Nationwide Analysis
Abstract Number: 2553

Predictors of Biologic and Targeted Synthetic DMARD Initiation for Rheumatoid Arthritis Across Underserved Patient Groups: Insights from a National Cohort Study
Abstract Number: 1587

Predictors of Body Mass Index in an Early Systemic Sclerosis Cohort
Abstract Number: 1482

Predictors of Clinical Response to Intravenous Secukinumab Among Patients with Axial Spondyloarthritis: A Post Hoc Analysis of a Phase 3 Trial
Abstract Number: 2354

Predictors of Clinical Response to Intravenous Secukinumab Among Patients with PsA: A Post Hoc Analysis of a Phase 3 Trial

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].